Stage 4 NSCLC is not curable but it is treatable.
For example:
These symptoms may be accompanied byfatigue,unintentional weight loss, andloss of appetite.
Treatments
Because stage 4 NSCLC has spread beyond the lungs, it is considered inoperable.
Caiaimage/Martin Barraud/OJO +/Getty Images
It cannot be cured, but it is treatable.
New medications have helped people live longer, fuller lives while managing this disease.
Your healthcare provider will probably recommend that you undergo genetic testing before you begin any other treatment.
These TKIs don’t work for all EFGR mutations, though.
Examples include the drugs Krazati (adagrasib) and Lumakras (sotorasib).
They target the KRAS G12C mutation, found in about 13% of people with NSCLC.
Both were recently approved for use in patients with advanced or metastatic disease after other therapies have been tried.
Chemotherapy
Historically,chemotherapywas the main option available to advanced lung cancer patients.
Those who have genomic alterations, such as EGFR mutations, tend not to respond as well.
Clinical Trials
Treatments for lung cancer are continually being researched and improved upon.
The National Cancer Institute (NCI) runsclinical trialsthat test new treatments for advanced non-small cell lung cancer.
you’re able to use theironline databaseto search for trials seeking participants.
Learn about clinical trials.
Consider joining asupport group.
This makes it more difficult to treat, and even less likely that treatment will cure you.
A variety of factors, including treatment key in, contribute to the survival rate of stage 4 NSCLC.
Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P.Lung cancer: Biology and treatment options.Biochim Biophys Acta.
2017;23(2):118-126. doi:10.5152/dir.2016.16187
American Cancer Society.Non-small cell lung cancer stages.
American Cancer Society.Signs and symptoms of lung cancer.
2019;131:69-77. doi:10.1016/j.lungcan.2019.03.008
U.S. Food and Drug Administration.Rybrevant label.
U.S. Food and Drug Administration.Lumakras label.
2022;12:882940. doi:10.3389/fonc.2022.882940
National Cancer Institute.Non-small cell lung cancer treatment (PDQ)patient version.
Cho J.Immunotherapy for non-small-cell lung cancer: current status and future obstacles.Immune Netw.
2018;24(23):5792-5806. doi:10.1158/1078-0432.CCR-17-3620
National Cancer Institute.Clinical trials information for patients and caregivers.
National Cancer Institute.Non-small cell lung cancer treatment (PDQ)health professional version.
American Cancer Society.Treatment choices for non-small cell lung cancer, by stage.
2021;11:761042. doi:10.3389/fonc.2021.761042
American Cancer Society.Lung cancer survival rates.
American Cancer Society.Cancer facts & figures 2020.
Faithi A, Brahmer J.Chemotherapy for advanced stage non-small cell lung cancer.Seminars in Thoracic and Cardiovascular Surgery.
20(3):210-6. doi:10.1053/j.semtcvs.2008.09.002
